FCB
BEAM icon

First Command Bank’s Beam Therapeutics BEAM Stock Holding History

First Command Bank’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$13K – 450
2021
Q2 		$13K Hold
100
– – ﹤0.01% 353
2021
Q1 		$8K Hold
100
– – ﹤0.01% 368
2020
Q4 		$8K Buy
+100
New +$4.92K ﹤0.01% 323

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Command Bank's BEAM Position: Q3 2021 in Review

First Command Bank sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 100 shares — an estimated $13K sold.

First Command Bank first reported a position in BEAM in Q4 2020 and held it in 3 quarters. The position peaked at $13K in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • First Command Bank reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • First Command Bank sold 100 Beam Therapeutics shares in Q3 2021, an estimated $13K.
  • First Command Bank first reported a position in Beam Therapeutics in Q4 2020 and held it in 3 quarters.
  • First Command Bank's Beam Therapeutics position peaked at $13K in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on First Command Bank's 13F filing for Q3 2021, filed 16 Dec 2021.